TABLE 3.
CT phase | No. CTs (%) | No. randomized CTs (total no. 71) (92%) | Standard arm placebo | Standard arm control | Standard arm other drug |
---|---|---|---|---|---|
Phase 1 | 1 (1.3) | 1 (1.3) | 0 | 0 | 1 (1.3) |
Phase 2 | 12 (15.6) | 9 (11.7) | 2 (2.6) | 5 (6.5) | 2 (2.6) |
Phase 3–2/3 | 53 (68.8) | 53 (68.8) | 26 (33.8) | 15 (19.5) | 12 (15.6) |
Phase 4 | 4 (5.2) | 4 (5.2) | 4 (5.2) | 0 | 0 |
NA/UN | 7 (9.1) | 4 (5.2) | 1 (1.3) | 2 (2.6) | 1 (1.3) |
CT, clinical trial; NA, not applicable; UN, unknown.